GLYCOLIPIDS IN DIFFERENTATION AND ONCOGENESIS

Information

  • Research Project
  • 3479311
  • ApplicationId
    3479311
  • Core Project Number
    R35CA042505
  • Full Project Number
    5R35CA042505-07
  • Serial Number
    42505
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1987 - 37 years ago
  • Project End Date
    5/31/1993 - 31 years ago
  • Program Officer Name
  • Budget Start Date
    6/1/1991 - 33 years ago
  • Budget End Date
    5/31/1992 - 32 years ago
  • Fiscal Year
    1991
  • Support Year
    7
  • Suffix
  • Award Notice Date
    5/24/1991 - 33 years ago

GLYCOLIPIDS IN DIFFERENTATION AND ONCOGENESIS

The dramatic changes in glycolipid composition and metabolism associated with cellular differentiation and oncogenesis suggest a specific role of membrane glycolipids in these processes. Previous studies have revealed that many tumor-associated antigens as well as developmentally-regulated antigens are glycolipids. Some of these antigens are modified or incompatible blood group antigens. On the other hand, ubiquitous gangliosides such as GM3 or GM1 may have a basic function in regulating cell proliferation and cell adhesing. Some evidence has been provided for a possible effect of membranes gangliosides on growth factor receptors such as EGF, PDGF, FGF, and transferrin. GM3 or GM1 inhibit tyrosine phosphorylation of the PDGF receptor, while GM3 inhibits that of the EGF receptor. Based on these findings, we propose to study the following projects: (1) A search for new glycolipid tumor-associated markers and their expression as related to various stages of cancer progression. (2) Specificities of blood group determinants as influenced by their carrier carbohydrates. (3) Oncofetal alteration of blood group determinants and their carrier carbohydrates, particularly expression of the globo-series blood group antigens and incompatible A-like antigens in human cancer. (4) A possible role of glycolipids in cell recognition during embryogenesis and differentiation of teratocarcinoma. (5) Cell growth inhibition and differentiation induction by exogenous addition of gangliosides, and the mechanism of such effects. (6) The effect of anti-carbohydrate antibodies on cell growth and differentiation. These studies may greatly enrich our knowledge of: (1) the molecular basis of tumor markers, their heterogeneity as related to phenotypic variation of human tumor cell population, and the steps of cancer progression; and (2) the molecular basis of cell recognition and adhesion through glycolipids, and the mechanism of aberrant cell proliferation of cancer cells.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R35
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
  • Study Section Name
  • Organization Name
    BIOMEMBRANE INSTITUTE
  • Organization Department
  • Organization DUNS
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    98119
  • Organization District
    UNITED STATES